Metastatic data was only the beginning.
Drs. Hamilton and Vidal reveal how DESTINY-Breast05 and DESTINY-Breast11 are poised to move T-DXd into curative-intent care. They analyze the results that are not just improving outcomes, but reshaping the future of HER2+ treatment across all stages.
Why Moving T-DXd to the Curative Setting Matters
You may also like
Recommended Videos
